On 27 May 2025, PegBio Co., Ltd. (2565.HK, PegBio Co) successfully listed on the Main Board of the Hong Kong Stock Exchange (HKEx), raising a total of approximately HKD 301 million. CBI is honored to participate in the due diligence work for this IPO Project.

PegBio Co. is a China-based company primarily engaged in the discovery and development of innovative therapies. Their products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus, obesity, non-alcoholic steatohepatitis, opioid-induced constipation and congenital hyperinsulinemia.

In this IPO project, CBI primarily assisted the sponsor team in conducting due diligence on the company group, its directors, senior management, shareholders and suppliers. In addition to the basic information such as litigation, bankruptcy, winding-up and media records, CBI also assisted the sponsor team in conducting related company search and reputation intelligence. The due diligence project globally covered 8 countries and regions, including China, Hong Kong, Japan, the United States, the United Kingdom and Ireland.